DK3628331T3 - Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum - Google Patents

Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum Download PDF

Info

Publication number
DK3628331T3
DK3628331T3 DK19205936.8T DK19205936T DK3628331T3 DK 3628331 T3 DK3628331 T3 DK 3628331T3 DK 19205936 T DK19205936 T DK 19205936T DK 3628331 T3 DK3628331 T3 DK 3628331T3
Authority
DK
Denmark
Prior art keywords
anticholinergic
corticosteroid
adrenergic
beta
preparation
Prior art date
Application number
DK19205936.8T
Other languages
English (en)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3628331(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Application granted granted Critical
Publication of DK3628331T3 publication Critical patent/DK3628331T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DK19205936.8T 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum DK3628331T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16
EP16801982.6A EP3377108B1 (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Publications (1)

Publication Number Publication Date
DK3628331T3 true DK3628331T3 (da) 2021-09-27

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
DK16801982.6T DK3377108T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DK19205980.6T DK3620176T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DK19205936.8T DK3628331T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK16801982.6T DK3377108T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DK19205980.6T DK3620176T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum

Country Status (35)

Country Link
US (4) US10086004B2 (da)
EP (3) EP3377108B1 (da)
JP (1) JP6963548B2 (da)
KR (1) KR20180082443A (da)
CN (1) CN108289962B (da)
AR (1) AR106688A1 (da)
AU (1) AU2016356858B2 (da)
CL (1) CL2018001298A1 (da)
CO (1) CO2018005141A2 (da)
CY (3) CY1123042T1 (da)
DK (3) DK3377108T3 (da)
EA (1) EA037716B1 (da)
ES (3) ES2895687T3 (da)
GE (2) GEP20207157B (da)
HR (3) HRP20211598T1 (da)
HU (3) HUE056441T2 (da)
IL (1) IL259329B (da)
LT (3) LT3620176T (da)
MA (3) MA50488B1 (da)
MD (3) MD3377108T2 (da)
ME (1) ME03778B (da)
MX (1) MX379853B (da)
MY (1) MY186229A (da)
PE (1) PE20181488A1 (da)
PH (1) PH12018501022A1 (da)
PL (3) PL3620176T3 (da)
PT (3) PT3620176T (da)
RS (3) RS62404B1 (da)
SA (1) SA518391570B1 (da)
SG (2) SG10201912093YA (da)
SI (3) SI3377108T1 (da)
TW (1) TWI731891B (da)
UA (1) UA125019C2 (da)
WO (1) WO2017085004A1 (da)
ZA (1) ZA201803168B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3621590B1 (en) 2017-05-11 2021-09-01 Chiesi Farmaceutici S.p.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
MA48620A (fr) * 2017-05-11 2021-04-28 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
WO2020198716A1 (en) * 2019-03-27 2020-10-01 Kemin Industries, Inc. Methods for preparing metal carboxylates in one-pot reaction
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
TWI495468B (zh) 2009-12-23 2015-08-11 吉斯藥品公司 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物
BR112012032330A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
MX369311B (es) * 2012-12-06 2019-11-05 Chiesi Farm Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
KR102275904B1 (ko) 2013-07-11 2021-07-13 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제

Also Published As

Publication number Publication date
MA50488B1 (fr) 2021-09-30
EP3377108B1 (en) 2020-02-19
RS62404B1 (sr) 2021-10-29
DK3377108T3 (da) 2020-04-20
MY186229A (en) 2021-06-30
IL259329B (en) 2020-10-29
HUE056441T2 (hu) 2022-02-28
NZ742474A (en) 2024-11-29
SI3628331T1 (sl) 2021-11-30
HUE049751T2 (hu) 2020-10-28
AR106688A1 (es) 2018-02-07
GEP20207157B (en) 2020-10-12
LT3377108T (lt) 2020-07-10
SI3377108T1 (sl) 2020-05-29
HRP20200537T1 (hr) 2020-06-26
US20200368252A1 (en) 2020-11-26
MX2018005977A (es) 2018-08-29
MX379853B (es) 2025-03-11
PL3620176T3 (pl) 2021-11-22
MA50488A (fr) 2021-05-19
CN108289962A (zh) 2018-07-17
ES2895687T3 (es) 2022-02-22
BR112018009807A8 (pt) 2019-02-26
MA50487A (fr) 2021-04-28
TWI731891B (zh) 2021-07-01
SA518391570B1 (ar) 2022-03-27
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
US10772896B2 (en) 2020-09-15
PE20181488A1 (es) 2018-09-18
CY1124475T1 (el) 2022-07-22
RS60171B1 (sr) 2020-05-29
US10966991B2 (en) 2021-04-06
EP3377108A1 (en) 2018-09-26
HUE056260T2 (hu) 2022-02-28
PH12018501022B1 (en) 2018-12-17
CL2018001298A1 (es) 2018-09-14
EP3620176A1 (en) 2020-03-11
JP6963548B2 (ja) 2021-11-10
ZA201803168B (en) 2019-07-31
GEAP202014783A (en) 2020-04-27
EA201890966A1 (ru) 2018-11-30
BR112018009807A2 (pt) 2018-11-06
ES2891073T3 (es) 2022-01-26
JP2019501876A (ja) 2019-01-24
US20170136035A1 (en) 2017-05-18
PH12018501022A1 (en) 2018-12-17
IL259329A (en) 2018-07-31
MD3628331T2 (ro) 2021-12-31
MA43256B1 (fr) 2020-05-29
PL3377108T3 (pl) 2020-09-07
US20180360849A1 (en) 2018-12-20
EP3628331A1 (en) 2020-04-01
KR20180082443A (ko) 2018-07-18
AU2016356858B2 (en) 2021-06-24
MA50487B1 (fr) 2021-09-30
MD3377108T2 (ro) 2020-07-31
RS62506B1 (sr) 2021-11-30
TW201722404A (zh) 2017-07-01
EA037716B1 (ru) 2021-05-13
MA43256A (fr) 2018-09-26
SG11201804050QA (en) 2018-06-28
HRP20211600T1 (hr) 2022-01-21
PT3620176T (pt) 2021-09-28
CY1124490T1 (el) 2022-07-22
EP3620176B1 (en) 2021-08-11
CA3005290A1 (en) 2017-05-26
US11628175B2 (en) 2023-04-18
PT3377108T (pt) 2020-04-08
ES2783855T3 (es) 2020-09-18
DK3620176T3 (da) 2021-09-20
US10086004B2 (en) 2018-10-02
HRP20211598T1 (hr) 2022-01-07
AU2016356858A1 (en) 2018-05-31
WO2017085004A1 (en) 2017-05-26
PL3628331T3 (pl) 2021-11-08
SI3620176T1 (sl) 2021-11-30
SG10201912093YA (en) 2020-02-27
ME03778B (me) 2021-04-20
LT3628331T (lt) 2021-11-10
CY1123042T1 (el) 2021-10-29
CN108289962B (zh) 2021-09-14
PT3628331T (pt) 2021-10-20
US20210177866A1 (en) 2021-06-17
CO2018005141A2 (es) 2018-09-28
EP3628331B1 (en) 2021-08-11
UA125019C2 (uk) 2021-12-29

Similar Documents

Publication Publication Date Title
DK3628331T3 (da) Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3689379T3 (da) Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
HUE059158T2 (hu) Eljárás pridopidin elõállítására
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3383436T3 (da) Forbedret fremgangsmåde til fremstilling af indocyaningrønt
DK3460102T3 (da) Fremgangsmåde til fremstilling af en elektrokatalysator
DK3237054T3 (da) Indretning til fremstilling og påføring af en medicinsk substans
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
PL3256154T3 (pl) Preparat farmaceutyczny zawierający przeciwciało
DK3442944T3 (da) Fremgangsmåde til fremstillingen af 4-aminoindanderivater og relaterede aminoindanamider
IL271388B (en) Improved process for preparing imetelstat
DK3148976T3 (da) Fremgangsmåde til fremstilling af dihydroisoxazolderivater
DK3187280T3 (da) Fremgangsmåde til fremstillingen af en formulering og formulering
KR20180084801A (ko) 중실형 부품의 제조를 위한 제조 장치, 그리고 그 제조 장치를 이용한 중실형 부품의 제조 방법
TH1601000099A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด
HUE047523T2 (hu) Eljárások indazol-származékok elõállítására
TH1501005391A (th) องค์ประกอบทางเภสัชกรรมแบบผงละเอียด